Dominican company based in Santo Domingo · We only ship within the Dominican Republic · No international shippingDominican Republic only · No international shipping
ES Home Catalog Education COAs Calculator Founder
PT-141 Bremelanotide
Renova Verification
  • ✓≥99% purity by HPLC + mass spectrometry
  • ✓Independent Janoshik 3rd-party analysis
  • ✓−20°C lyophilized · 2–8°C reconstituted
🧪 View COA →
Home › Products › Sexual & Aesthetics › PT-141 Bremelanotide
← Back to catalog Sexual & AestheticsAvailable

PT-141 Bremelanotide (10 mg)

MelanocortinFDASexual health
$115 USD10 mg/vial
🧪 Bacteriostatic water — needed to reconstitute the lyophilized vial
💰 Buy by volume
3+ of one
Save 15%
5+ of one
Save 25%
★ Wholesale
10+ of one
Save 40%
🔀 Mix & Match · across different products: 3+ items 10% · 5+ 15% · 7+ 20%
The best discount per product is applied automatically at checkout (they don't stack). Excludes bacteriostatic water; Retatrutide and Tirzepatide only get same-product volume. Can't be combined with promo codes.
🧪 COA❄️ Cold chain🛡️ Replacement guarantee🔒 Secure payment📦 Nationwide shipping🇺🇸 cGMP · ISO 9001 guidelines · COA

Bremelanotide — FDA-approved melanocortin agonist for female sexual dysfunction. Acts via CNS, not vascular like PDE5 inhibitors.

  • Mechanism: Melanocortin agonist (mainly MC4R).
  • Evidence: Phase 3 human evidence (bremelanotide) for female sexual dysfunction.
  • In context: FDA-approved as Vyleesi. Renova supplies it for research only. Nausea, transient BP rise, skin darkening with repeated use.
Research range · SC
1.75 mg · as needed (max 1/day)
🟢 Clinical evidence

Ranges cited in research literature. Not a usage recommendation. For research use only.

📋 Technical datasheet · Compound specifications
CompoundPT-141 Bremelanotide
Origin🇺🇸 From US-based suppliers that follow strict cGMP & ISO 9001 guidelines
FormLyophilized in sterile vial (or pre-mixed solution depending on SKU)
Molecular formulaC50H68N14O10
Molecular weight1025.18 g/mol
Purity≥99% by HPLC + mass spectrometry (Janoshik Analytical)
StorageLyophilized: −20°C to −80°C, dry, dark · Reconstituted: 2–8°C · stability varies by peptide (see the reconstitution guide and the product COA)
Recommended solventBacteriostatic water (0.9% benzyl alcohol) or 0.9% saline
Cold chain2–8°C in transit · controlled thermal packaging
UseResearch Use Only (RUO). Not intended for human or veterinary use.

Typical values for this compound category. For product-specific data, see the corresponding COA at /en/coa/.

This product is exclusively for research purposes. Not intended for human use, consumption, or therapeutic applications. For laboratory use only under qualified supervision.

PT-141 (Bremelanotide): research profile

PT-141, international nonproprietary name bremelanotide, is a cyclic heptapeptide — Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH — that differs from Melanotan II only at the C-terminus: a free carboxylic acid instead of the amide. It was identified as the active metabolite of Melanotan II after spontaneous erections were observed in that compound's tanning trials, and Palatin Technologies developed it as a centrally acting melanocortin agonist.

It acts mainly on the MC4R receptor in the hypothalamus, with affinity also for MC3R and little action at MC1R, so its pigmentary effect is far smaller than Melanotan II's. Unlike phosphodiesterase inhibitors it does not act on blood flow but on the central dopaminergic pathways of desire and arousal, which made it the first molecule of its class. Its half-life is about 2.7 hours.

Two Phase 3 trials (the RECONNECT program, more than 1,200 women) led to FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women; in men development was halted over the transient rise in blood pressure. The most frequent adverse effects in trials were nausea (around 40%), flushing, headache and, with repeated use, focal hyperpigmentation. Renova's product is not Vyleesi: it is PT-141 for research, not suitable for human use.

PT-141 (Bremelanotide) technical data

ClassCentrally acting melanocortin agonist (MC4R > MC3R), cyclic α-MSH analog
SequenceAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH (7 aa; differs from MT-II at the C-terminus)
CAS189691-06-3
OriginMetabolite of Melanotan II; developed by Palatin Technologies
Reported half-life≈ 2.7 hours (SC route)
Phase 3 dataRECONNECT program (> 1,200 participants); FDA approval 2019 as Vyleesi
Drug adverse effectsNausea (≈ 40%), flushing, headache, transient blood-pressure increase, focal hyperpigmentation
Regulatory statusMolecule FDA-approved (Vyleesi); Renova product is RUO

Questions about PT-141 (Bremelanotide)

Are PT-141 and bremelanotide the same?

Yes. PT-141 was Palatin's development code and bremelanotide is the international nonproprietary name; Vyleesi is the brand of the medicine the FDA approved in 2019. All refer to the same cyclic heptapeptide. Renova's product is the molecule as research material, not the medicine.

How does PT-141 differ from drugs like sildenafil?

Sildenafil and its analogs act on vascular tissue, increasing blood flow; PT-141 acts in the hypothalamus, on the MC4R receptors involved in the pathways of desire and arousal. They are independent mechanisms, which is why PT-141 was studied in an indication — hypoactive desire — where vasodilators have no effect.

Why was PT-141 development in men halted?

Because of the transient blood-pressure increase that accompanies administration, seen in the initial intranasal trials; the FDA asked for that program to stop and development was redirected to the subcutaneous route and the female indication, which is the one that reached approval.

Does PT-141 tan the skin like Melanotan II?

Far less. Its affinity for MC1R, the melanocyte receptor, is low, although with repeated use in trials focal hyperpigmentation of the face, gums and breasts was described in about 1% of participants. Melanotan II, by contrast, is a potent MC1R agonist and pigmentation is its main effect.

Related reading: PT-141 (Bremelanotide): A Melanocortin Receptor Agonist · Melanotan II: Melanocortin Agonist

Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.

Questions? Write us

Your Order

Your cart is empty